Condition: Hypochondroplasia · Sponsor: BioMarin Pharmaceutical
The purpose of this study is to evaluate the safety and efficacy of daily administration of vosoritide in participants with HCH aged 0 to \< 36 months over a 52-week period.
This description comes directly from the study's public registry record.
Trial Specialist · 1-800-983-4587 · medinfo@bmrn.com
Always discuss trial participation with your own doctor first.
| Phoenix Children's Hospital - Thomas Campus (Main) | Phoenix, Arizona, United States | Recruiting |
| Cedars-Sinai Medical Center | Los Angeles, California, United States | Not Yet Recruiting |
| Benioff Children's Hospital - Oakland | Oakland, California, United States | Recruiting |
| Children's National Medical Center | Washington D.C., District of Columbia, United States | Recruiting |
| Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago, Illinois, United States | Recruiting |
| The Johns Hopkins University School of Medicine | Baltimore, Maryland, United States | Recruiting |
| University of Minneasota Masonic Children's Hospital | Minneapolis, Minnesota, United States | Recruiting |
| University of Missouri | Columbia, Missouri, United States | Recruiting |
| Cook Children's Endocrinology | Fort Worth, Texas, United States | Not Yet Recruiting |
| Children's Wisconsin - Fox Valley Hospital | Neenah, Wisconsin, United States | Not Yet Recruiting |
| Children's Health Queensland Hospital and Health Service | South Brisbane, Queensland, Australia | Not Yet Recruiting |
| Royal Children's Hospital Melbourne | Parkville, Victoria, Australia | Recruiting |
+ 14 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07126262